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Background/objectives: The pathologic relationship linking obesity and lipid disme-
tabolism with earlier onset of aging-related disorders, including cardiovascular disease 
(CVD) and type-2 diabetes (T2D), is not fully elucidate. Chronic inflammatory state, in 
obese individuals, may accelerate cellular aging. However, leukocyte telomere length 
(LTL), the cellular biological aging indicator, is elusively linked with obesity. Recent studies 
indicate that sterol 27-hydroxylase (CYP27A1) is an emerging antiatherogenic enzyme, 
that, by converting extrahepatic cholesterol to 27-hydroxycholesterol, facilitates choles-
terol removal via high-density lipoprotein-cholesterol (HDL-C). We tested the hypothesis 
that obese subjects who carry at least three copies of CYP27A1 low-hydroxylation (LH) 
activity genome-wide-validated alleles (rs4674345A, rs1554622A, and rs4674338G) 
present premature aging, as reflected in shorter LTL and higher levels of CVD/T2D risk 
factors, including reduced HDL-C.
subjects/methods: Obese subjects from SPHERE project {n =  1,457; overweight 
[body mass index (BMI) 25–30  kg/m2] 65.8% and severe-obese (BMI >  30  kg/m2) 
34.2%} were characterized for the presence from 0 to 6 LH-CYP27A1 allele copy num-
ber. Univariate and multivariable sex–age–smoking-adjusted linear-regression models 
were performed to compare CVD/T2D risk factors and biological aging (LTL) in relation 
to the combined BMI-LH groups: overweight-LH: 0–2, overweight-LH: 3–6, severe-
obese-LH: 0–2, and severe-obese-LH: 3–6.
results: Higher LTL attrition was found in severe-obese than overweight individuals 
(p < 0.001). Multivariable model reveals that among severe-obese patients those with 
LH: 3–6 present higher LTL attrition than LH: 0–2 (p < 0.05). Univariate and multivariable 
models remarkably show that insulin resistance is higher both in overweight-LH: 3–6 
vs overweight-LH: 0–2 (p < 0.001) and in severe-obese-LH: 3–6 vs severe-obese-LH: 
0–2 (p < 0.0001), and HDL-C is lower in overweight-LH: 3–6 than overweight-LH: 0–2 
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(p < 0.05 and p < 001). Finally, most of the well-known (i.e., blood pressure, heart rate, 
waist to hip, triglycerides, and HDL-C) and novel CVD risk factors [i.e., inflammation 
markers (C-reactive protein, leukocytes, and chemoattractant protein-1), fibrinogen, and 
glucose homeostasis (i.e., insulin resistance, and glycated hemoglobin)] are substantially 
(p < 0.0001) altered in severe-obese-LH: 0–2 vs overweight-LH: 0–2, pointing to the fact 
that obesity leads to worsen the CVD/T2D risk factor profile.
conclusion: Our study supports evidence that CYP27A1 genetic characterization 
identifies persons at higher risk to develop CVD and T2D, on which better converge 
preventive measures, and opens new perspectives on mechanisms that link obesity with 
aging-related disorders.
Keywords: obesity, cholesterol, hDl, genotyping, cardiovascular diseases, diabetes mellitus type 2, insulin 
sensitive obese, telomere shortening
inTrODUcTiOn
The dramatic escalation of obesity and overweight prevalence, 
leading to earlier onset of aging-related cardiovascular disease 
(CVD), represents an emerging worldwide public health prob-
lem (1). This preventable disorder, often associated with cho-
lesterol dismetabolism (2, 3) and aging-related diseases (4–6), 
is challenging to prevent and to treat, since the heterogeneous 
and complex causes, including interactions between genetic pre-
disposition and environmental factors, are almost unknown (7).
The sterol 27-hydroxylase (CYP27A1) is a largely distributed 
mitochondrial P450 cytochrome enzyme, that, by converting 
extrahepatic cholesterol to 27-hydroxycholesterol (27OHC), 
the most abundant circulating oxysterol, primarily promotes its 
elimination. Extrahepatic CYP27A1, mainly expressed in the 
vascular endothelium (8) and in macrophages (9), in fact con-
tributes to speed 27OHC elimination by the so-called “reverse 
transport,” from the periphery to the liver (10) where it is further 
converted to bile acids, the major cholesterol catabolic pathway. 
The flux of 27OHC from periphery to the liver is regarded as 
an emerging antiatherogenic mechanism flanking the classical 
HDL-dependent cholesterol reversed transport (11, 12). Lack 
in CYP27A1 sterol hydroxylation activity due to mutations 
in the CYP27A1, found in patients with cerebrotendinous 
xanthomatosis disease, determines cholesterol accumulation in 
the vascular endothelium and severe premature development of 
atherosclerosis even though normal serum cholesterol concen-
trations (13). In addition, mice, lacking in the CYP27A1 with the 
consequent lessening in 27OHC production, present a failing in 
estrogen-related cardiovascular protection (14). 27OHC, in fact, 
Abbreviations: 27OHC, 27-hydroxycholesterol; BMI, body mass index; CRP, 
C-reactive protein; CVD, cardiovascular disease; T2D, type-2 diabetes; CYP27A1, 
sterol 27-hydroxylase; DBP, diastolic blood pressure; ECG, electrocardiogram; 
ERs, estrogen receptors; HDL-C, high-density lipoprotein-cholesterol; HOMA, 
homeostasis model assessment; IFNγ, interferon gamma; IL10, interleukin-10; 
LDL, low-density lipoprotein; LH, low-hydroxylation activity; LTL, leukocyte 
telomere length; MCP-1, chemoattractant protein-1; MIPα, macrophage inflam-
matory proteins alpha; SBP, systolic blood pressure; TNFα, tumor necrosis factor 
alpha; Total-C, total-cholesterol.
directly antagonizes the transcriptional and non-transcriptional 
functions of estrogen receptors in vascular endothelial and 
smooth muscle cells, flanking the cardioprotective effects of 
estrogens (15). Taken together, these data suggest a protective 
role of normal CYP27A1 hydroxylation activity in the develop-
ment of atherosclerosis and the consequent CVD risk. Reduced 
CYP27A1 activity has been also found in genome wide study 
to be mainly related to three CYP27A1 SNPs (rs4674345 A>G, 
rs1554622 A>C, and rs4674338 G>A), each SNP presented 
similar contribution that explained 60–65% of its activity reduc-
tion (16). Likewise, these CYP27A1 genetic polymorphisms 
could also diminish the cholesterol reverse transport, favor its 
accumulation in extrahepatic tissues, and therefore increase the 
individual atherogenic and CVD susceptibility.
Obesity may accelerate aging through chronic inflammation 
(17) and oxidative stress (18). Several observational studies have 
investigated the association between obesity and aging through 
assessment of telomere length in blood leukocytes (19, 20). The 
telomere in fact refers to terminal DNA–protein complexes at 
the chromosome, which primarily functions to maintain chro-
mosomal stability (21). Telomere shortening in leukocytes (LTL) 
is regarded as marker of biological aging, but the association 
between obesity and LTL remains elusive (19, 20). Conversely, 
shorter LTL has been associated with higher risk of mortality 
and CVD events in several studies, including among the most 
recent works (21–25). Moreover, few prospective studies have 
also shown that decreased LTL predicts future development of 
type-2 diabetes (T2D) (26, 27).
In view of advances in tailored health-care management, 
in this study, we test the hypothesis that overweight and 
severe-obese subjects who carry an high number of CYP27A1 
low-hydroxylation activity alleles (rs4674345 A, rs1554622 A, 
and rs4674338 G) are more likely to present altered cholesterol 
metabolism, premature aging at the cellular level as reflected 
in shorter LTL, as well as higher levels of CVD risk factors as 
compared to those with normal-hydroxylation activity. The aim 
is to identify persons more susceptible to develop CVD on which 
better converge preventive measures. To test this hypothesis, we 
genetically characterized overweight and severe-obese subjects of 
the SPHERE (“Susceptibility to Particle Health Effects, miRNAs 
TaBle 1 | Demographic and lifestyle characteristics.
characteristics categories n = 1,457
Sex Male 397 (27.25%)
Female 1,060 (72.75%)
Age, years Mean ± SD 52.26 ± 13.53
Body mass index (BMI), kg/m2 Mean ± SD 33.6 ± 5.4
BMI categorical Overweight 959 (65.8%)
Severe obese 498 (34.2%)
Waist to hip, cm Mean ± SD 101.8 ± 13.2
Year of enrollment 2010 130 (8.92%)
2011 408 (28.00%)
2012 367 (25.19%)
2013 313 (21.48%)
2014 239 (16.4%)
Smoking Never smoker 713 (49.00%)
Ex-smoker 511 (35.12%)
Actual smoker 231 (15.88%)
Cigarettes smokeda (n/day) ≤5 65 (28.38%)
5–10 59 (25.76%)
10–15 42 (17.9%)
15–20 48 (20.52%)
20–40 17 (7.42%)
Pack/years (n = 1,380) Median [IQR]
Among current and 
former smokers
15 [23–45]
Including non-smokers 0 [14–25]
Time since quitting (n = 495) Median [IQR] 13.14 [18–27]
Alcohol intake category (glasses) Drink-unit/week 
(mean ± SD)
Wine 1.96 ± 3.76
Beer 0.39 ± 0.99
Hard liquor 0.23 ± 1.12
Physical activity Sedentary 866 (59.4%)
Active 457 (31.4%)
Sporty 49 (3.4%)
Active-sporty 44 (3.0%)
Missing 41 (2.8%)
aAmong current smokers.
IQR = Q1 (first quartile)–Q3 (third quartile): interquartile range.
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and Exosomes”) project by the three functional polymorphisms 
of CYP27A1 (rs4674345 A/G, rs1554622 A/C, and rs4674338 
G/A) and characterized each subject with a score ranging from 0 
to 6, referring to the copy number of low-hydroxylation alleles. 
The combination of allele copy number and body mass index 
(BMI) categories was evaluated in relation to biological aging 
(LTL) and to well-known and novel CVD risk factors, such as 
inflammation and coagulation markers, and a CVD risk score 
[calculated according to the Cardiovascular Risk Calculator1].
MaTerials anD MeThODs
study subjects
Study population consists of n = 1,457 participants enrolled in 
the SPHERE project.2 The recruitment was conducted at the 
Center for Obesity and Work, Fondazione IRCCS Ca’ Granda 
Ospedale Maggiore Policlinico, Milan, Italy period September 
2010 and until March 2015. Each participant signed an informed 
consent form, which had been approved by the ethics committee 
of the Ca’ Granda Ospedale Maggiore Policlinico, Milan institu-
tion (approval number 1425), in accordance with principles of 
the Helsinki Declaration. The eligibility criteria for participants 
were as follows: (1) older than 18 years at enrollment; (2) obese/
overweight according to the following definition: overweight is 
defined as a BMI between 25 and 30  kg/m2, obesity is defined 
as a BMI of 30 kg/m2 or more; (3) resident in Lombardy at the 
time of the recruitment; and (4) agreement to sign an informed 
consent and donate blood and urine samples. Exclusion criteria 
include the following: previous diagnosis of cancer, heart disease, 
or stroke in the last year or other chronic diseases such as multiple 
sclerosis, Alzheimer’s disease, Parkinson’s disease, depression, 
bipolar disorder, schizophrenia, and epilepsy (28, 29). Weight and 
height to calculate BMI were measured the same day of blood 
drawing. BMI was calculated as the weight in kilograms divided 
by the square of height in meters. The main characteristics of 
study participants are reported in Table 1. Most participants are 
females (72.75%).
epidemiological and clinical Data 
collection
As part of the routine protocol, for each subject presenting at 
the Center, an extensive physical examination was performed. 
Pulmonary functions were measured, at the same day of blood 
drawing, with an electronic flow volume spirometer V-max 22 
with Autobox (SensorMedics), according to European Respiratory 
Society/American Thoracic Society guidelines (ERS/ATS 2005). 
Tests were performed on patients in the sitting position and were 
repeated until at least three reproducible forced expiratory curves 
were obtained. A resting electrocardiogram and rhythm strip 
were also recorded, and blood pressure was measured with the 
participant supine, after 5 min of rest. Whole blood was collected 
into ethylenediaminetetraacetic acid (EDTA) tubes from each 
participant by venous phlebotomy after overnight fast.
1 http://cvrisk.mvm.ed.ac.uk/calculator/excelcalc.htm (Accessed: November 11, 2016).
2 http://users.unimi.it/sphere/ (Accessed: May 18, 2016).
Biochemical parameters were also collected using standard 
procedures. Briefly, all patients underwent routine laboratory 
determinations, including complete blood counts (n/mm3), 
C-reactive protein (CRP; mg/dl), total-cholesterol (Total-C), 
high-density lipoprotein (HDL), and low-density lipoprotein 
(LDL), triglycerides, serum creatinine, fasting blood glucose, 
homocysteine, glycated hemoglobin, postprandial glycemia, 
insulin level, 2-h post glucose insulin level, urinary pH, and uric 
acid (28, 29). Quantitative determination of fibrinogen in citrate 
plasma samples was obtained on automated I.L. Coagulation 
System (Instrumentation Laboratory S.p.A., Milan, Italy). Insulin 
resistance was quantified by the homeostasis model assessment 
(HOMA) index using the formula described by Matthews et al. 
(30): HOMA index =  [fasting serum insulin (mU/l) ×  fasting 
blood glucose] (mmol/l)/22.5. In addition, each study subject 
was asked to fill in a lifestyle questionnaire and to donate a 15 ml 
blood sample for molecular tests.
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lifestyle Questionnaire
As previously described in Ref. (28), the lifestyle questionnaire 
collected information on sociodemographic data (sex and age) 
residential area (complete address, characteristics of the house, 
and traffic), education (i.e., primary school or less, high school, 
and university), smoking (i.e., never, former, and current smok-
ers; cigarette smoked per day), history including passive smoking 
at home and at workplace, past and present health status of both 
the subjects and their first-degree relatives, medications in the 
last year, employment history (i.e., employee, unemployed, pen-
sioner, and housewife) and address of the plant of their current 
work (currently employed subjects only), physical activity levels 
and sedentary behavior, commuting time, and transport mode. 
The questionnaire was self-assessed at recruitment and checked 
by a trained assistant, in presence of the subject, to ensure the 
completeness of information. Data originally recorded on paper 
(i.e., questionnaire) were then transferred into spreadsheets and 
anonymized of personally identifying information and identified 
through a five-digit randomly assigned barcode.
Biological sample collection
Specific laboratory Standard Operating Procedures have been 
developed to ensure quality control of every step involved in 
biospecimen collection and storage. Blood was collected using 
EDTA tubes (7  ml). Blood samples were transported from the 
Center for Obesity and Work to EPIGET laboratory (University 
of Milan) within 2  h from the phlebotomy. EDTA blood was 
processed to obtain whole DNA from peripheral blood leuko-
cytes. EDTA blood was centrifuged 1,100 × g for 15 min at room 
temperature to obtain platelet-free blood plasma and buffy coat. 
An aliquot of plasma was further centrifuged at 1,000, 2,000, and 
3,000 × g for 15 min at 4°C to remove cell debris. Biospecimens 
were tracked through a secure database that stores detailed infor-
mation on sample description, aliquoting, and freezer locations. 
Approximately 90% of study subjects donated a blood sample.
genotyping
DNA was isolated from frozen leukocytes as previously described 
in Ref. (29). The extracted DNA was stored at −20°C until 
shipping to the Department of Cardiac, Thoracic and Vascular 
Science, University of Padova, Italy. Genotyping was performed 
by commercially available TaqMan drug metabolism genotyp-
ing assays: C-2070266-20 “rs4674345” (Functionally Tested), 
C-2070139-10 “rs1554622” (Validated) and C-32303836-10 
“rs4674338” (Functionally Tested) (Life Technologies–Thermo 
Fisher, Milan, Italy). Reactions were set up based on the manu-
facturer’s protocol, and the samples were run in triplicate on a 
Steponeplus Real-Time instrument (Applied Biosystems, Foster 
City, CA, USA). Allelic discrimination was performed using the 
SDS software v2.3 (Applied Biosystems). Twenty-five microlitre 
reactions in 96-well plates included 12.5  µl TaqMan Universal 
PCR Master Mix, No AmpErase UNG (2×), 1.25  μl Drug 
Metabolism Genotyping Assay Mix (20×) (Applied Biosystems), 
and DNA 11.25 μl (1 ng/μl). Validated Assays are tested using 
gDNA from 45 individuals from four ethnicities. The minor allele 
frequency for each population is available and is shown to be 
>5% in at least one population. Functionally Tested Assays met 
minimum functionality criteria in testing of 20 DNA samples 
from three ethnic populations and both genders. Minor allele fre-
quency is not calculated. To find out whether the genotype was in 
Hardy–Weinberg equilibrium, distribution of the observed and 
expected genotype frequencies was compared using a chi-square 
test. For CYP27A1 genotype, values of 6, 5, 4, 3, 2 1, or 0 were 
attributed, referring to the presence of 6, 5, 4, 3, 2, 1, 0, copies 
of low hydroxylation (LH) activity rs4674345 A, rs1554622 A, 
rs4674338 G variants, respectively (as described in Table S1 in 
Supplementary Material) assuming the addictive effect of the 
presence of at least one allele at risk. In fact, each SNP showed 
similar contribution to CYP27A1 activity reduction that was 
0.62, 0.65, and 0.60%, respectively (16). To detect the higher effect 
related to CYP27A1 reduced activity, we therefore considered >3 
SNPs as cut point for statistical analysis. In this way, subjects with 
>3 LH alleles present at least a copy of each LH SNP.
cytokines Measurements
We used 50 µl plasma EDTA to quantify a custom panel of five 
cytokines using Luminex xMAP®-based technology (MYRIAD 
RBM, Inc., Austin, TX, USA), a multiplex immunoassay that 
simultaneously quantifies multiple protein analysts in a single 
run of the assay. In particular, we measured interferon gamma 
(IFNγ), macrophage inflammatory proteins alpha (MIPα), 
chemoattractant protein-1 (MCP-1), interleukin-10 (IL10), and 
tumor necrosis factor alpha (TNFα).
leukocyte Telomere length (lTl) 
Measurement
Seven milliliters of whole blood were collected into EDTA tubes 
from each participant by venous phlebotomy after overnight fast. 
Blood was centrifuged at 2,500  rpm for 15 min. The buffy coat 
fraction was transferred to a cryovial and immediately frozen 
at −80°C until use. DNA was extracted by the Wizard Genomic 
DNA purification kit (Promega, Madison, WI, USA), according 
to the manufacturer’s instructions. LTL was measured by using 
quantitative Real-Time PCR method by Cawthon (31). This 
assay measures relative LTL in genomic DNA by determining, 
respectively, the ratio of telomere repeat copy number (T) to single 
nuclear copy gene (S), T/S ratio, in a given sample relative to a 
reference DNA. As reference DNA, we used a pool DNA from 50 
participants randomly selected from the population (500 ng for 
each sample). The single-copy gene used in this study was human 
(beta) globin (hbg). A fresh standard curve, from the pool of 
control samples, ranging from 70 to 1.09  ng/µl (serial dilutions 
1:2), was included in every “T” and “S” PCR run, against a negative 
control (water); 30 ng of DNA sample was added to each reaction. 
Each sample was run in triplicate. A high-precision MICROLAB 
STARlet Robot (Hamilton Life Science Robotics, Bonaduz AG, 
Switzerland) was used for transferring volume of 7 µl reaction mix 
and 3 µl DNA (10 ng/µl) in a 384-well format plate as previously 
described in Ref. (28, 29). All PCR reactions were performed on 
a 7900HT Fast Real Time PCR System (Applied Biosystems). The 
thermal cycling profile for both amplicons began with 50°C for 
2 min followed by incubation at 95°C for 2 min to activate the 
AmpliTaq DNA polymerase. For telomere PCR, activation was 
followed by 2 cycles of 15 s at 95°C and 15 s at 49°C and 35 cycles 
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of 15 s at 95°C, 10 s at 62°C, and 15 s at 74°C. For hbg, activation 
was followed by 35 cycles of 15 s at 95°C and 1 min at 58°C. At the 
end of each real-time PCR reaction, a melting curve was added 
for both T and S PCRs to verify the specificity of amplification. 
The average of the three T measurements was divided by the 
average of the three S measurements to calculate the average T:S 
ratio, i.e., relative telomere length. T:S ratio is normalized with T:S 
obtained from the reference pool of DNA inserted in each plate. 
A measure was considered acceptable if the SD among triplicate 
measures was <0.25. The coefficient of variation for the average T:S 
ratio of samples analyzed over three consecutive days was 8.7%, 
similar to the reproducibility originally reported for this method.
cardiovascular risk calculation
A 10-year cardiovascular risk score for estimating the probability 
of CVD was calculated by a Cardiovascular Risk Calculator, 
available at the web site http://cvrisk.mvm.ed.ac.uk/calculator/
excelcalc.htm. This web page contains a downloadable version 
of the Framingham and ASSIGN scores, in an Excel spreadsheet, 
for use by persons wishing to calculate risk for large numbers 
of patients. The calculation takes into consideration age, sex, 
smoking behaviors (yes vs no), diabetes (yes: glycated hemo-
globin ≥ 47.5 mmol/mol, no: glycated hemoglobin < 47.5 mmol/
mol), systolic blood pressure (SBP), Total-C, and high-density 
lipoprotein-cholesterol (HDL-C).
statistical analysis
Descriptive statistical data were obtained for the demographic/
lifestyle variables and for CVD risk factors. Respectively, mean 
and SD were calculated for normally distribute data, median and 
interquartile range for non-normally distributed data. Number 
and percentage were reported for categorical variables. For 
CYP27A1 genotype, values of 6, 5, 4, 3, 2, 1, or 0 were attributed, 
referring to the presence of 6, 5, 4, 3, 2, 1, 0, copies of LH activity 
rs4674345 A, rs1554622 A, and rs4674338 G variants, respectively 
(as described in Table S1 in Supplementary Material) assuming 
the addictive effect of the presence of the allele at risk. In fact, each 
SNP showed similar contribution to CYP27A1 activity reduction 
that was 0.62, 0.65, and 0.60%, respectively (16). To detect the 
higher effect related to CYP27A1 reduced activity, we therefore 
considered more than three SNPs as cut point for statistical analy-
sis. In this way, subjects with more than three LH alleles present 
at least a copy of each LH SNP.
The presence of 0–2 and 3–6 LH CYP27A1 alleles categorizes 
patients in LH: 0–2 and LH: 3–6 groups. We compare CVD risk 
factors of study participants according to BMI level: overweight 
(BMI < 35 kg/m2) vs severe-obese (BMI ≥ 35 kg/m2) using the 
χ2-test or Fisher’s exact test for categorical variables and the t-test 
or Wilcoxon rank-sum test for continuous variables.
Patients were then categorized in four BMI-CYP27A1 catego-
ries: overweight-LH: 0–2 the lowest risk group, overweight-LH: 
3–6, severe-obese-LH: 0–2, and finally severe-obese-LH: 3–6, 
the highest risk group. In particular, the effects of genotype are 
studied in two different phenotypic background in following 
comparisons: overweight-LH: 3–6 vs overweight-LH: 0–2 and 
severe-obese-LH: 3–6 vs severe-obese-LH: 0–2. The effects of 
phenotype are studied in different phenotypic background with 
the same genotype, in the following comparison: severe-obese-
LH: 0–2 vs overweight-LH: 0–2.
Simple univariate and multivariable linear regression models 
were carried out to evaluate the relationship between subjects 
belonging to the four CYP27A1 LH-BMI categories and CVD 
risk factors [Total-C, HDL-C, triglycerides, waist to hip, SBP, 
diastolic blood pressure (DBP), and heart rate], T2D (glycated 
hemoglobin  ≥  47.5  mmol/mol), biological aging (LTL), and 
inflammation and coagulation markers (CPR, fibrinogen, and 
leukocytes). Regression diagnostics were performed separately 
for each model, and outliers were excluded from regression 
analysis by dropping observations with studentized residuals that 
exceeded +3 or −3. The number of removed outliers ranged from 
a minimum of 0 to a maximum of 3.
We checked regression assumptions by performing diagnostic 
tests for each model, which included the Shapiro–Wilk test to 
verify normality of residuals and the White test to verify the 
homogeneity of variance of the residuals. Assumptions were sat-
isfied for all continuous variables, except for HDL-C, LTL, CRP, 
leukocytes which were transformed on a logarithmic scale (log-
transformed). The independent variables used in multivariable 
models were selected a priori and included general characteristics 
potentially associated with outcomes: sex, age, and smoking status 
(yes, no, and ex-smokers). For variables modeled on original scale, 
we calculate beta and 95% confidence intervals (CIs) from linear 
regression models, expressing the change in arithmetic mean of 
outcome switching from one category to the own reference one 
(overweight-LH: 0–2 or severe-obese-LH: 0–2). For log-trans-
formed variables, we reported the % change = (exp(β) − 1) × 100 
and 95% CIs expressing the percent change in geometric mean 
of variables switching from one category (overweight-LH: 3–6, 
severe-obese-LH: 3–6, and severe-obese-LH: 0–2) to the own 
reference one (overweight-LH: 0–2 or severe-obese-LH: 0–2).
Given the particular shape of cytokines variables (IFNγ, 
MIPα, MCP-1, IL10, and TNFα) distribution, which are all left-
censoring because values that fall at or below some threshold are 
censored, we used univariate and multivariable Tobit regression 
adjusted for sex, age, smoking status (yes, no, and ex-smokers) to 
estimate the association between CYP27A1 LH-BMI categories 
and cytokines. Tobit regression is able to provide better consistent 
estimates of the parameters than the simple linear regression. Also 
in this case, we reported beta and 95% CIs, expressing the change 
in arithmetic mean of outcome switching from one category to 
the own reference one (overweight-LH: 0–2 or severe-obese- 
LH: 0–2).
Afterward, we computed odds ratios (ORs) and 95% CIs 
for the association of CYP27A1 LH-BMI category with insulin 
resistance (yes: 0 < HOMA index < 2.5; no: HOMA index > 2.5). 
Multivariable logistic regression models were adjusted for sex, 
age, and smoking status (yes, no, and ex-smokers). Finally, a 
univariate simple regression model was fitted to evaluate the 
association of CYP27A1 LH-BMI category with the 10-year 
cardiovascular risk score estimating the probability of CVD. 
Statistical analysis was carried out using SAS software (version 
9.2; SAS Institute, Milan, Italy). A two-sided p-value of less than 
0.05 was considered statistically significant.
TaBle 2 | Cardiovascular disease and type-2 diabetes (T2D) risk factors according to body mass index levels.
characteristics all (1,457) Overweight (N = 959) severe-obese (N = 498) p-Value**
Blood pressure, mmhg
Systolic blood pressure 125.8 ± 15.7 123.5 ± 14.9 130.3 ± 16.4 <0.001
Diastolic blood pressure 78.5 ± 9.36 77.4 ± 8.8 80.7 ± 10 <0.001
Above 140/90, mmHg 67 (4.60%) 24 (2.5%) 43 (8.6%) 0.2017
Below 140/90, mmHg 1,390 (95.40%) 935 (97.5%) 455 (91.4%) –
Heart rate, bpm 67.6 ± 10.5 66.3 ± 10.1 69.9 ± 11 <0.001
Total-cholesterol, mg/dl 212.6 ± 40.4 213.1 ± 39.9 211.5 ± 41.3 0.4898
High-density lipoprotein-cholesterol, mg/dl 57 [20] 59 [22] 54 [17] <0.001
Low-density lipoprotein-cholesterol, mg/dl 133.6 ± 35.4 133.2 ± 35.3 134.4 ± 35.4 0.5314
Triglycerides, mg/dl 107 [67] 99 [67] 118 [73] <0.001
Total-cholesterol/high-density lipoprotein-cholesterol 3.83 ± 1.2 3.7 ± 1.2 4.0 ± 1.2 <0.001
Glucose, mg/dl 98.6 ± 24.9 96.4 ± 22.4 102.9 ± 28.7 <0.001
Glycated hemoglobin, mmol/mol 40.3 ± 8.6 39.2 ± 7.6 42.3 ± 10.0 <0.001
Insulin level, mIU/L 14.9 ± 11.4 12.7 ± 8.5 19.1 ± 14.7 <0.001
Type-2 diabetesb
Yes 171 (11.9%) 84 (8.9%) 87 (17.7%) <0.001
 No 1,270 (88.1%) 864 (91.1%) 406 (82.4%) –
insulin resistancec
Yes 774 (54.9%) 425 (46.1%) 349 (71.5%) <0.001
No 637 (45.2%) 498 (54.0%) 139 (28.5%) –
complete blood count (n*103/µl)
Leukocytes 6.65 [2.24] 6.44 [2.16] 7.01 [2.26] <0.001
Red blood cells 4.8 ± 0.5 4.8 ± 0.5 4.8 ± 0.4 0.0652
Mean corpuscolar colume 85.3 ± 7.6 85.4 ± 8.2 85.1 ± 6.2 0.3336
Platelets 248.9 ± 59.5 246.6 ± 56.8 253.3 ± 64.1 0.0497
inflammation markers
C-reactive protein, mg/dl 0.28 [0.42] 0.22 [0.31] 0.46 [0.57] <0.001
cytokines
IFNγ, pg/ml 9.3 [12.35] 9.2 [11.35] 9.3 [12.35] 0.2018
MIPα, pg/ml 68.0 [75] 67 [76] 70 [76] 0.1885
MCP-1, pg/ml 169.0 [82] 165 [79] 174 [85] <0.001
IL10, pg/ml 3.7 [2.7] 3.6 [2.7] 4.1 [2.8] <0.001
TNFα, pg/ml 5.5 [5.8] 5.05 [5.6] 6.3 [6.4] 0.0305
coagulation markers
Fibrinogen, mg/dl 331.2 ± 63.3 321.7 ± 59.8 349.8 ± 65.8 <0.001
Biological aging
LTL (T/S) 1.05 ± 0.30 1.1 ± 0.3 1.0 ± 0.3 <0.001
genotype
cYP27a1 lh groupa
LH: 0–2 358 (24.6%) 234 (24.4%) 124 (24.9%) 0.8337
LH: 3–6 1,099 (75.4%) 725 (75.59%) 374 (75.1%) –
Variables were expressed as mean ± SD and median [IQR] if continuous and N (%) as categorical.
**p-Value from t-test or Wilcoxon Rank sum test for continuous variables and χ2 for categorical variables.
aPresence of 0–2 and 3–6 low-hydroxylation (LH) alleles (rs4674345 A, rs1554622 A, and rs4674338 G) categorizes patients in LH: 0–2 and LH: 3–6 groups.
bType-2 diabetes (yes: glycated hemoglobin ≥ 47.5 mmol/mol; no: glycated hemoglobin < 47.5 mmol/mol).
cInsulin resistance [yes: 0 < homeostasis model assessment (HOMA) index < 2.5; no: HOMA index > 2.5].
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resUlTs
Table  2 shows that quite all CVD risk factors such as classic 
modifiable risk factors (SBP and DBP), heart rate, lipid profile 
(Total-C, HDL-C, and triglyceride), glucose homeostasis (insulin 
resistance and glycated hemoglobin), and novel risk factors such 
as inflammation markers (leukocytes, CRP, MCP-1, and IL10), 
coagulation markers (fibrinogen), and biological aging indicator 
(LTL) were significantly (p < 0.001) different between overweight 
and severe-obese individuals.
Univariate unadjusted and multivariable sex–age–smoking-
adjusted linear regression models are presented in Tables 3 and 4.
The effects of genotype (LH: 3–6 vs LH: 0–2 with the same phe-
notypic conditions) were studied in the comparisons overweight- 
LH: 3–6 vs overweight-LH: 0–2 and severe-obese-LH: 3–6 vs 
severe-obese-LH: 0–2. Multivariable sex–age–smoking-adjusted 
(Table  4) shows that severe-obese-LH: 3–6 present higher LTL 
attrition (β  =  −5.86; p  =  0.039) than severe-obese-LH: 0–2. 
Univariate unadjusted and multivariable sex–age–smoking-
adjusted linear regression models (Tables  3 and 4) show that 
insulin resistance was higher in overweight-LH: 3–6 vs over-
weight-LH: 0–2 (OR = 1.34; p < 0.001) and in severe-obese-LH: 
3–6 vs severe-obese-LH: 0–2 (OR = 1.41; p < 0.0001). Moreover, 
HDL-C was quite significantly reduced (β = −3.50, p < 0.0679) 
TaBle 3 | Univariate analysis.
cYP27a1 lh-BMi category
Variables Overweight-lh: 3–6  
vs overweight-lh: 0–2
severe-obese-lh: 0–2  
vs overweight-lh: 0–2
severe-obese-lh: 3–6  
vs severe-obese lh: 0–2
effecta 95% ci p-Value effect 95% ci p-Value effect 95% ci p-Value
cardiovascular disease risk factors
Total-cholesterol 4.40 −1.58 10.37 0.1490 −1.45 −10.26 7.36 0.7468 4.28 −3.94 12.50 0.3073
High-density lipoprotein-cholesterolb −3.50 −7.12 0.26 0.0679 −9.45 −14.42 −4.20 <0.001 −0.58 −5.68 4.79 0.8283
Triglyceridesb 4.08 −2.89 11.55 0.2576 18.40 6.90 31.13 0.0012 1.10 −8.09 11.22 0.8212
Waist to hip 0.23 −1.30 1.77 0.7650 17.53 15.26 19.80 <0.001 −0.22 −2.33 1.90 0.8396
Systolic blood pressure 0.87 −1.41 3.14 0.4557 7.74 4.36 11.12 <0.0001 −0.41 −3.56 2.75 0.7997
Diastolic blood pressure 0.52 −0.84 1.89 0.4516 4.31 2.28 6.33 <0.0001 −0.78 −2.67 1.11 0.4164
Heart rate 0.71 −0.83 2.25 0.3628 4.00 1.72 6.28 0.0006 0.15 −1.98 2.27 0.8923
Type-2 diabetes
Glycated hemoglobinb 0.28 −2.35 2.99 0.8355 8.97 4.78 13.31 <0.001 1.88 −5.34 1.83 0.3243
Oxidative stress
LTLb 0.43 −3.87 4.91 0.8486 0.38 −5.90 7.08 0.9089 −5.61 −11.13 0.25 0.0602
inflammation and coagulation markers
C-reactive proteinb −6.54 −19.47 8.46 0.3727 62.04 30.17 101.72 <0.0001 19.40 −2.66 46.43 0.0888
Fibrinogen −5.41 −14.65 3.84 0.2515 28.42 14.62 42.22 <0.0001 −5.76 −18.68 7.16 0.3819
Leukocytesb −0.02 −0.05 0.02 0.3474 0.07 0.02 0.12 0.0096 1.52 −3.45 6.74 0.5560
cytokinesc
MCP-1 2.51 −4.29 9.79 0.4789 12.63 1.72 24.69 0.0221 0.64 −8.47 10.64 0.8957
Ord 95% ci p-Value Ord 95% ci p-Value Ord 95% ci p-Value
Insulin resistance (yes vs no) 1.49 1.10 2.01 <0.001 3.81 2.36 6.14 0.0022 1.37 0.86 2.20 <0.0001
aFor variables in the original scale, we reported as effect the coefficient beta and 95% confidence intervals (CIs) expressing the change in arithmetic mean of outcome switching from 
one category to the own reference one [overweight-low hydroxylation (LH): 0–2 or severe-obese LH: 0–2].
bFor log-transformed variables, we reported as effect Δ% = (exp(β) − 1) × 100 and 95% CIs expressing the percent change in geometric mean of variables switching from one 
category to the own reference one (overweight-LH: 0–2 or severe-obese-LH: 0–2).
cCytokines were modeled by means of Tobit regression. Also in this case, we reported as effect the coefficient beta and 95% CIs, expressing the change in arithmetic mean of 
outcome switching from one category to the own reference one (overweight-LH: 0–2 or severe-obese-LH: 0–2).
dOdds ratio (OR) and 95% CIs from adjusted logistic regression for sex, age, and smoking.
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in overweight-LH: 3–6 vs overweight-LH: 0–2 (Table  3). The 
unadjusted and sex–age–smoking-adjusted regression diagnostic 
models we applied for this borderline difference (data not showed) 
indicated that HDL-C was significantly reduced in overweight-LH: 
3–6 vs overweight-LH: 0–2 [β = −4.16 (95% CI = −7.60; −0.61, 
p = 0.0223) and β = −3.89 (95% CI = −6.9; −0.72, p = 0.0167)].
The effects of phenotype (severe-obese vs overweight with the 
same genotype), studied in the comparison severe-obese-LH: 
0–2 vs overweight-LH: 0–2, are evident in most (71%) of the 
well-known (blood pressure, heart rate, waist to hip, triglycer-
ides, and HDL-C) and novel CVD risk factors [inflammation 
markers (CRP, leukocytes, and MCP-1), fibrinogen and glucose 
homeostasis (insulin resistance and glycated hemoglobin)], but 
not in LTL. The results point to the fact that obesity leads to 
worsen CVD risk factor profile.
In the whole, the 10-year CVD risk (Figure  1) raises from 
overweight–LH: 3–6 (β: 1.08, 95% CI: −0.1 to 2.28, p = 0.0754), 
severe-obese–LH: 0–2 (β: 2.40, 95% CI: 0.64–4.15, p < 0.0076), and 
even more in severe-obese-LH: 3–6 (β: 2.98, 95% CI: 1.66–4.30, 
p < 0.001) compared with the reference (overweight-LH: 0–2).
DiscUssiOn
Our study, exploring the hypothesis that overweight and severe-
obese individuals, who carry more than three LH cholesterol 
CYP27A1 variants (rs4674345 A, rs1554622 A, and rs4674338 
G; LH: 3–6 group), are more likely to present higher CVD risk 
factors and premature biological aging, founds that LTL attrition 
and insulin resistance were significant higher in severe-obese-LH: 
3–6 than severe-obese-LH: 0–2, while insulin resistance was also 
greater in overweight-LH: 3–6 compared with overweight-LH: 
0–2. In the entire sample population, LTL was significant lower 
in severe-obese than overweight.
Moreover classic CVD risk factors (blood pressure, heart rate, 
waist to hip, triglycerides, and HDL-C) and novel CVD/T2D risk 
factors [inflammation markers (CRP, leukocytes, and MCP-1), 
fibrinogen, and glucose homeostasis (insulin resistance and 
glycated hemoglobin)] were significant altered in severe-obese vs 
overweight with the same genotype (LH: 0–2) point to the fact 
that obesity represents a harmful condition that leads to worsen 
the CVD risk factor profile.
lTl and Obesity
Several observational studies have investigated the association 
between obesity and LTL (19, 20). Even if this association was 
found to be from weak to moderate and many studies did not 
reach statistical significance, there was a trend toward an inverse 
correlation between TL and obesity (19, 20). The only study that 
reported a positive association was conducted in women with 
systemic lupus erythematosus, and the authors state that this 
FigUre 1 | 10-Year cardiovascular disease (CVD)a risk according to CYP27A1 body mass index-low hydroxylation (LH) category. a10-Year CVD score calculated 
using Framingham equation. bWe reported as effect the coefficient beta and 95% confidence intervals from adjusted linear regression models [adjusted for sex, age, 
smoking, status (yes, no and ex-smokers)], expressing the change in arithmetic mean of outcome switching from one category to the reference one (overweight-
LH: 0–2). cReference: overweight-LH: 0–2.
TaBle 4 | Multivariable analysis.
cYP27a1 lh-BMi category
Variables Overweight-lh: 3–6  
vs overweight-lh: 0–2
severe-obese-lh: 0–2  
vs overweight-lh: 0–2
severe-obese-lh: 3–6 
 vs severe-obese-lh: 0–2
effecta 95% ci p-Value effect 95% ci p-Value effect 95% ci p-Value
cardiovascular disease risk factors
Total-cholesterol 3.89 −1.99 9.77 0.1947 −1.53 −10.19 7.14 0.7296 3.68 −4.39 11.75 0.3711
High-density 
lipoprotein-cholesterolb
−2.85 −6.16 0.57 0.1014 −8.28 −12.84 −3.48 <0.001 −1.36 −5.94 3.44 0.5709
Triglyceridesb 2.85 −3.84 10.00 0.4131 16.26 5.30 28.36 0.0029 1.58 −7.38 11.39 0.7394
Waist to hip −0.25 −1.51 1.02 0.7020 16.42 14.56 18.28 <0.001 0.13 −1.61 1.86 0.8835
Systolic blood pressure 0.36 −1.80 2.51 0.7467 6.76 3.56 9.96 <0.0001 -0.20 −3.19 2.78 0.8952
Diastolic blood pressure 0.36 −0.98 1.71 0.5968 3.95 1.95 5.94 0.0001 −0.66 −2.52 1.20 0.4877
Heart Rate 0.88 −0.66 2.41 0.2622 4.38 2.12 6.64 0.0002 0.03 −2.08 2.14 0.9760
Type-2 diabetes
Glycated hemoglobinb −0.05 −2.53 2.49 0.9695 8.21 4.29 12.28 <0.001 −1.83 −5.15 1.60 0.2910
Oxidative stress
LTLb 1.16 −2.97 5.47 0.5874 1.99 −4.10 8.46 0.5306 −5.86 −11.10 −0.31 0.039
inflammation and coagulation markers
C-reactive proteinb −5.62 −18.61 9.44 0.4436 65.32 32.99 105.48 <0.0001 18.41 −3.30 45.01 0.1019
Fibrinogen −5.90 −15.04 3.25 0.206 29.48 15.84 43.11 <0.0001 −7.07 −19.81 5.68 0.2770
Leukocytesb −2.17 −5.57 1.36 0.2246 7.75 2.28 13.51 0.005 1.30 −3.50 6.34 0.6027
cytokinesc
MCP-1 1.72 −4.91 8.81 0.6192 10.84 0.30 22.47 0.0435 0.64 −8.28 10.42 0.8933
Ord 95% ci p-Value Ord 95% ci p-Value Ord 95% ci p-Value
Insulin resistance (yes vs no) 1.34 0.97 1.84 <0.001 3.42 2.09 5.61 0.0036 1.41 0.88 2.27 <0.0001
aFor variables in the original scale, we reported as effect the coefficient beta and 95% confidence intervals (CIs) resulting from adjusted linear regression models [adjusted for sex, 
age, and smoking status (yes, no, and ex-smokers)], expressing the change in arithmetic mean of outcome switching from one category to the own reference one [overweight-low 
hydroxylation (LH): 0–2 or severe-obese-LH: 0–2].
bFor log-transformed variables, we reported as effect Δ% = (exp(β) − 1) × 100 and 95% CIs expressing the percent change in geometric mean of variables switching from one 
category to the own reference one (overweight-LH: 0–2 or severe-obese-LH: 0–2).
cCytokines were modeled by means of Tobit regression. Also in this case, we reported as effect the coefficient beta and 95% CIs, expressing the change in arithmetic mean of 
outcome switching from one category to the own reference one (overweight-LH: 0–2 or severe-obese-LH: 0–2).
dOdds ratio (OR) and 95% CIs from adjusted logistic regression for sex, age, and smoking.
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result might simply reflect a better disease control (32). Sex (33), 
ethnicity (34), and age (35) seem to be the main factors that mine 
this moderate association. The chances that the association—BMI 
with shorter LTL—could depend on factors other than BMI were 
minimized in our study because there is a prevalence of women, 
quite of the same age range and all are of the same ethnicity. 
The fact that, in the subgroup of CYP27A1 LH: 0–2 (n = 358), 
LTL was not significant in severe-obese vs overweight, it can be 
attributed to the lowered sample size of population.
Among the key factors that may explain the association 
between telomere attrition and obesity there are increased inflam-
matory processes linked to the oxidative stress that accompanies 
obesity (36). Obesity increases a pro-inflammatory state linked to 
hyperplasia and hypertrophy of adipocytes, and to adipose tissue 
hypoxia (37). This process likely induces increased production of 
adipokines, leading to a localized and systemic pro-inflammatory 
state with greater production of reactive species (38). Telomeres, 
as triple-guanine-containing sequences, are highly sensitive to 
damage by oxidative stress (39). The resulting damaged telomeric 
bases by double-strand breaks and/or interference with replica-
tion fork can induce a reduction in telomere length (40). Long-
standing exposure to these inflammatory conditions give rise to 
significant changes also in large and microscopic blood vessels, 
increased leukocyte adhesion, thrombus formation, and impaired 
vasomotor responses (41, 42). Telomere erosion in peripheral 
blood leukocytes, the biological aging clock, is accelerated by a 
local and systemic status of inflammation (43, 44), representing a 
fundamental mechanism linking obesity with related diseases, such 
as CVD. Coherently in our study, inflammation (CRP, leukocytes, 
and MCP-1) and coagulation markers (fibrinogen) were signifi-
cantly higher in severe-obese than overweight subjects. The clear 
significant association between increased BMI and LTL attrition 
adds further dowel which remarks the importance of obesity as a 
determinant of aging.
low-hydroxylation cYP27a1 Variants  
in severe Obese and shorter lTl
Sterol 27-hydroxylase is involved in cholesterol efflux, as it 
represents the first and rate-limiting step in reverse transport, 
by transforming cholesterol to 27OHC in extrahepatic tissues. 
CYP27A1 is in fact expressed at high levels in the macrophages 
and vascular endothelium (45). Low activity of CYP27A1 
results in shoddier cholesterol efflux (46). In fact, patients with 
cerebrotendinous xanthomatosis, lacking of CYP27A1, due to 
the deleterious effect of gene deletion mutations, present choles-
terol abnormally deposited in different tissues, such as vascular 
endothelium, central nervous system, and crystalline lens (47). 
In addition, these patients significantly present low levels of 
HDL-C and are predisposed to develop premature aging-related 
diseases, including atherosclerosis and coronary heart disease 
(48). Our findings that LTL are lowered in the LH: 3–6 than LH: 
0–2 severe-obese patients would suggest that telomere erosion 
is further accelerated by local and systemic status of inflamma-
tion as a consequence of the reduced cholesterol removal from 
peripheral tissues. This points out the importance by these 
CYP27A1 variants in identify, among severe-obese, those that 
present higher biological aging and are therefore at higher risk of 
developing premature aging-related diseases, than those without 
these harmful variants. The influence we found of CYP27A1 
polymorphism on these fundamental inflammatory players in 
obesity, including LTL, would underline the importance of this 
enzyme not only in cholesterol removal, via reverse transport, 
but also in the consequent aging response.
low-hydroxylation cYP27a1 Variants  
and higher insulin resistance
The risk of being insulin resistance (HOMA index <  2.5) is 
evident among severe-obese and overweight individuals too 
with low-hydroxylation CYP27A1 polymorphism. Insulin 
resistance is a feature of T2D and is also implicated in obesity 
and in CVD development (49). The compensatory hyperinsu-
linemia due to insulin resistance induces free fatty acid efflux 
from adipose tissue, raises plasma triacylglycerol but reduces 
HDL-C, by activation of cholesterol ester transfer protein that 
increases its clearance by the kidneys (50, 51). Actually, in 
our study, we found that HDL-C was significantly reduced in 
overweight-LH: 3–6 vs overweight-LH: 0–2. Likewise, it is the 
loss of insulin sensitivity that explains why obese individuals are 
more likely to develop T2D and CVD, but not all overweight/
obese individuals present insulin resistance. In light of these 
observations, it seems reasonable to suggest that insulin resist-
ance is the link between overweight/obesity and the adverse 
clinical syndromes related to excess adiposity. Therefore, it 
is important to identify those overweight/obese individuals 
who are also insulin resistance, to initiate the most intensive 
therapeutic effort in this subgroup. The observation that the 
risk of being insulin resistance is higher among severe-obese 
and overweight individuals with low-hydroxylation CYP27A1 
activity, open new perspectives in examining persons at higher 
risk to develop T2D and CVD, representing a new possible 
target/challenge in T2D and CVD prevention research.
low-hydroxylation cYP27a1 Variants  
in Overweight reduces hDl-c
HDL-C, which we found reduced in overweight LH: 3–6 com-
pared with overweight LH: 0–2, represents the most important 
system of cholesterol removal from tissues, transporting it back 
(“reverse transport”) to the liver, where cholesterol is processed 
for excretion through the bile (52). Low HDL-C levels promote 
atherogenesis and increase CVD risk. Macrophages are the 
principal artifice of cholesterol efflux via the reverse transport 
(53). Patients with cerebrotendinous xanthomatosis significantly 
present low levels of HDL-C and are predisposed to develop 
cholesterol accumulation diseases, including atherosclerosis, 
coronary heart disease, cataracts, tendon xanthomas as well as the 
presence of progressive neurologic dysfunction (48). Low HDL-C 
levels have also been implicated in modifying survival and in the 
onset of respiratory impairment in amyotrophic lateral sclerosis 
patients (54). Since we found that HDL-C levels are lowered in 
the LH: 3–6 group, our study would suggest the importance also 
of these CYP27A1 variants in regulating cholesterol metabolism/
efflux on the risk to develop “cholesterol accumulation diseases,” 
CVD included.
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low-hydroxylation cYP27a1 Variants  
and 10-Year cardiovascular risk score
Likewise, the 10-year cardiovascular risk score, which estimates 
the 10-year probability of CVD in individuals who have not 
already developed major atherosclerotic disease, raises in 
overweight and even more in severe-obese subjects with low-
hydroxylation cholesterol CYP27A1 variants. This score is con-
sidered an aid to make clinical decisions about how intensively to 
intervene on lifestyle and whether to use antihypertensive, lipid 
lowering medication and aspirin. The study’s findings, therefore, 
support the hypothesis that the CYP27A1 genetic characteriza-
tion better identifies persons at higher risk to develop CVD on 
which better converge preventive measures, representing a new 
possible target in personalized medicine.
conclusion
Our research on CYP27A1 polymorphism opens new perspec-
tives in investigation of the adverse health effects of obesity and 
in identifying persons at higher risk to develop T2D and CVD 
on which better converge preventive measures. CYP27A1 has the 
potential to act both as susceptibility marker in T2D and CVD 
development and as a key event in the chain of events connect-
ing obesity to T2D and CVD development, representing a new 
possible target in personalized preventive medicine of chronic 
degenerative diseases. In addition, the clear significant role of 
CYP27A1 on the relationship between BMI and LTL attrition 
adds further insight into mechanism linking obesity with aging.
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